Can Amgen’s new-and-improved Kyprolis kick-start myeloma sales?
Dive Brief: Strong initial demand for Amgen and Novartis’ new preventive migraine therapy Aimovig has reinforced expectations of blockbuster sales — for one analyst at least. Since Aimovig’s approval in … Continue Reading Aimovig launch bolsters hopes for blockbuster sales
On Aug. 5, 2014, Scott Hayes of Wilson, N.C. received some of the worst news imaginable. He was diagnosed with amyotrophic lateral sclerosis (ALS). He was given three to five … Continue Reading Given a Death Sentence, ALS Patients Wait for Potential Disease Cure
Earlier this year, BIO and TEConomy Partners released their 2018 “Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry” report. It was the eighth biennial report, and focused on the economic progress and the footprint … Continue Reading A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year
Last week, Israel-based Teva Pharmaceutical released what tried to be an optimistic second-quarter financial report. Despite revenues that had decreased by 18 percent and softening sales of its biggest product, Copaxone, the company’s … Continue Reading A Deep Dive into Teva Pharma Financials Shows Significant Weakness and Optimism
In July, Pfizer’s anti-smoking medication Chantix got something of a facelift. Noted actor Ray Liotta of “Goodfellas” fame became the face of the medication. In the commercial, which is airing on most … Continue Reading Pharma Companies Create Memorable Ad Campaigns for Branded Products
Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that … Continue Reading Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?
In the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart? With some of … Continue Reading Five things to know about biosimilars right now
What Did Ian Read Learn From Trump? Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump’s thinking on drug … Continue Reading Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk
While Novartis and Amgen work to keep up with pent-up demand for their newly launched migraine treatment Aimovig, a new study backed by both pharma companies looks at real-world needs of … Continue Reading Novartis study validates need for better migraine treatment, as Novartis-Amgen drug hits market
Drug companies have been hit hard this year. Public opinion, trust and reputation of pharmaceutical companies appear to be eroding, according to a new analysis from the research consulting … Continue Reading These are the most — and least — reputable drug companies in the US
2018 is already half over, but expect fireworks now that President Trump has turned his attention to seeking lower drug prices. The Tweeter-in-Chief publicly shamed companies that have tried to … Continue Reading 7 companies to watch during Q2 earnings
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously untreated liver … Continue Reading Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough
Amgen, headquartered in Thousand Oaks, California, and UCB, based in Brussels, Belgium, resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab). The FDA rejected the original BLA in July 2017, requesting … Continue Reading Amgen and UCB Take Another Shot at Osteoporosis Drug
CAR-T companies are on the rise, supported by growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within … Continue Reading CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies
When Kris Bakowski was diagnosed with Alzheimer’s disease in 2002, the Georgia resident felt relieved to finally put a name to the fog that was slowly enveloping her … Continue Reading Why Hope Endures For An Alzheimer’s Treatment — And Biogen Could Be First